New Hampshire Abortion-Inducing Drugs Safety Act (HB 1662)
This law was last updated on Jun 29, 2016
HB 1662 would prohibit anyone from knowingly giving, selling, dispensing, administering, or otherwise providing or prescribing any abortion-inducing drug to a pregnant woman for the purpose of inducing an abortion in that pregnant woman or enabling another person to induce an abortion in a pregnant woman, unless the person who does so is a physician and the provision or prescription of the abortion-inducing drug satisfies the protocol authorized by the FDA, as outlined in the printed FPL for the drug or drug regimen.
The bill also requires a physician to examine the pregnant woman and document, in the woman’s medical chart, gestational age and intrauterine location of the pregnancy prior to giving, selling, dispensing, administering, or otherwise providing or prescribing the abortion-inducing drug.
Every pregnant woman to whom a physician gives, sells, dispenses, administers, or otherwise provides or prescribes any abortion-inducing drug should be provided with a copy of the drug’s label.
The physician prescribing any abortion-inducing drug, or an agent of said physician, would need to schedule a follow-up visit for the woman at approximately 14 days after administration of the abortion-inducing drug to confirm that the pregnancy is completely terminated and to assess the degree of bleeding.
The bill would require the physician prescribing the abortion-inducing drug to have a signed contract with a physician who agrees to handle complications and be able to produce that signed contract on demand by the patient or by the department. The physician who contracts to handle emergencies must have active admitting privileges and gynecological/surgical privileges at a hospital designated to handle any emergencies associated with the use or ingestion of the abortion-inducing drug.
Every pregnant woman to whom a physician prescribes any abortion-inducing drug shall receive the name and phone number of the contracted physician and the hospital at which that physician maintains admitting privileges can handle any emergencies.
If the physician knows that the woman who uses the abortion-inducing drug for the purpose of inducing an abortion experiences (during or after the use) an adverse event, the physician would need to provide a written report of the adverse event within 3 days of the event to the FDA via the Medwatch Reporting System and to the board of medicine.
A person who intentionally, knowingly, or recklessly violates any provision of this bill would be guilty of a class A felony. They may also face civil and professional disciplinary action.